Clinical Trial Update: Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target [NA]

View source ↗

Summary

A clinical trial is validating TSPO as a novel neuroimmunomodulatory target for multiple sclerosis. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Snippet

Sponsor: Imperial College London | Conditions: Multiple Sclerosis | NA | Status: RECRUITING